Pharmaceutical giants are squaring off against telehealth companies and pharmacies selling custom-made versions of the hot ...

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

But if you’re taking a drug on purpose to s--- your brains out, just so you lose 10 pounds, honey, we liked you a little chubbier." Ozempic, which is a semaglutide injection, was originally ...

But if you’re taking a drug on purpose to s—t your brains out, just so you lose 10 pounds, honey, we liked you a little chubbier.” The FDA first approved Ozempic to help people with Type 2 ...

Introducing Hot Shots, a series that examines how Ozempic and other GLP-1 drugs have transformed the way we think about our bodies, weight loss, and wellness. Ozempic and other GLP-1 drugs like it ...

Those drugs are commonly known by names such as Ozempic, Wegovy and Zepbound. That’s because the drugs, while popular and highly sought after, are expensive and can push up the total cost of ...

Studies show promising results for semaglutide as a potential treatment for alcohol use disorder. Semaglutide, a GLP-1 drug, was initially used for type 2 diabetes treatment and weight loss.

The FDA has declared the shortages as “resolved," removing the drugs from its shortage list. Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, March 8 ...

The Food and Drug Administration wants bulk production of the copycats to stop—starting Wednesday for pharmacy-prepared versions of Zepbound and later in the spring for knockoffs of Ozempic and ...